Document 0793 DOCN M94B0793 TI HIV lymphomas frequently carry mutations in the c-myc protein (Meeting abstract). DT 9412 AU Spangler G; Gaidano G; Hamdy N; Dalla-Favera R; Magrath I; Bhatia K; Pediatric Branch, NCI, Bethesda, MD 20892 SO Proc Annu Meet Am Assoc Cancer Res; 35:A1141 1994. Unique Identifier : AIDSLINE ICDB/94602827 AB Non-Hodgkin's lymphomas, particularly high grade B cell lymphomas, are the most frequent malignancies diagnosed in patients infected with HIV. We have previously reported the occurrence of point mutations in the protein coding region of c-myc in approximately 60% of SNCL in non-HIV infected patients. We have now screened the entire coding region of c-myc in thirty HIV lymphomas and assessed the integrity of the c-myc protein. Our results indicate that the c-myc protein is mutated in 50% of the HIV lymphomas and 75% of small non-cleaved HIV lymphomas. Among 14 other histological subtypes tested (3 large cell non-cleaved, 3 Ki-1 positive and 8 immunoblastic lymphomas) only 2 immunoblastic lymphomas carried c-myc mutations. Unlike intronic mutations, coding region mutations were seen in some tumors that lacked a myc/Ig translocation. However, among 19 tumors with a myc/Ig translocation, 9/11 which lacked EBV had a c-myc mutation, whereas only 2 of 8 EBV positive tumors contained a translocation. These mutations, unlike those that occur in the intron, were also seen in tumors with no evidence of c-myc translocation. The implications of these mutations in the genesis of HIV lymphomas will be discussed. DE Cell Transformation, Neoplastic/GENETICS Chromosome Aberrations Gene Expression Regulation, Neoplastic/PHYSIOLOGY Gene Frequency Human Lymphoma, AIDS-Related/*GENETICS Mutation/*GENETICS Proto-Oncogene Proteins c-myc/*GENETICS MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).